Core Insights - Analysts project Travere Therapeutics (TVTX) will report a quarterly loss of $0.58 per share, a 50% increase year over year, with revenues expected to reach $73.44 million, reflecting a 63% increase from the same quarter last year [1] Earnings Estimates - Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 9.9%, indicating a reassessment by covering analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts estimate 'Revenue- Tiopronin products / Thiola' will reach $24.03 million, a decrease of 4.7% from the previous year [5] - 'Revenue- FILSPARI' is forecasted to be $45.31 million, indicating a significant year-over-year increase of 208.3% [5] - 'Revenue- License and collaboration revenue' is expected to be $4.77 million, reflecting a decrease of 7.2% from the year-ago quarter [5] Stock Performance - Travere shares have increased by 24.7% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.7% [6] - With a Zacks Rank of 3 (Hold), TVTX is anticipated to closely follow overall market performance in the near term [6]

Core Viewpoint - Travere Therapeutics, Inc. is set to report its fourth quarter and full year 2024 financial results on February 20, 2025, after the U.S. financial markets close, followed by a conference call and webcast to discuss the results and provide a business update [1] Company Information - Travere Therapeutics is a biopharmaceutical company focused on developing therapies for patients with rare diseases, emphasizing the urgent need for treatment options [3] - The company collaborates with the rare disease community to identify, develop, and deliver life-changing therapies, aiming to understand the diverse perspectives of rare patients [3]

Travere Therapeutics (TVTX) shares ended the last trading session 12.6% higher at $23.75. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.5% gain over the past four weeks.The sudden soaring of the stock price was observed following Travere's announcement that it has completed a Type C meeting with the FDA and intends to submit a supplemental new drug application (sNDA) for traditional approval of Filspari in tre ...

Core Insights - Travere Therapeutics has completed a Type C meeting with the FDA and plans to submit a supplemental New Drug Application (sNDA) for FILSPARI, targeting focal segmental glomerulosclerosis (FSGS) [1][2] - If approved, FILSPARI could be the first and only approved treatment for FSGS, a rare kidney disorder affecting over 40,000 patients in the U.S. [2][5] - The sNDA submission will rely on data from the Phase 3 DUPLEX and Phase 2 DUET studies, which have shown promising results in reducing proteinuria [1][6][7] Company Updates - The sNDA submission is expected around the end of the first quarter of 2025 [1] - The CEO of Travere Therapeutics expressed optimism about the sNDA submission and highlighted the urgent need for treatment options for FSGS [2] - A conference call and webcast will be held to discuss these updates, scheduled for February 11, 2025, at 8:30 a.m. ET [3][4] Study Insights - The Phase 3 DUPLEX study is noted as the largest interventional study in FSGS, achieving significant results in reducing proteinuria [6][7] - The Phase 2 DUET study demonstrated a greater than two-fold reduction in proteinuria compared to irbesartan, indicating the efficacy of FILSPARI [7] - Both studies support the importance of proteinuria reduction as a key endpoint in FSGS treatment, aligning with findings from the PARASOL workgroup [2][8] Disease Context - FSGS is characterized by progressive kidney scarring and is a leading cause of kidney failure, with no currently approved pharmacologic treatments [5] - The disorder affects both adults and children, highlighting the need for effective therapies [5]

Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025 Company remains on track to provide regulatory update on sparsentan in FSGS by its fourth quarter 2024 earnings call SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutic ...

Core Viewpoint - Travere Therapeutics (TVTX) shows potential for significant upside, with a mean price target of $27.20 indicating a 42.6% increase from the current price of $19.08 [1] Price Target Analysis - The mean estimate consists of 15 short-term price targets with a standard deviation of $8.33, indicating variability among analysts [2] - The lowest estimate is $18, suggesting a 5.7% decline, while the highest estimate predicts a 120.1% increase to $42 [2] - A low standard deviation indicates strong agreement among analysts regarding price movement direction [7] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about TVTX's earnings prospects, with a positive trend in earnings estimate revisions [9] - The Zacks Consensus Estimate for the current year has risen by 0.9% over the past month, with no negative revisions [10] - TVTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as they can mislead investors [3][5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT. A live webcast of the presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics ...

Group 1 - Travere Therapeutics received full approval for its sparsentan 200/400 mg tablets, branded as Filspari, for the treatment of IgA nephropathy (IgAN) [1] - IgAN is a chronic kidney disease caused by the immune system producing abnormal antibodies [1] Group 2 - The article does not provide additional relevant content for further summarization.

Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Homocystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactiv ...

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject to customary ...